246 related articles for article (PubMed ID: 25645199)
1. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
[TBL] [Abstract][Full Text] [Related]
2. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI
Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721
[TBL] [Abstract][Full Text] [Related]
3. The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes.
Guha N; Erotokritou-Mulligan I; Bartlett C; Cowan DA; Bassett EE; Stow M; Sönksen PH; Holt RI
Drug Test Anal; 2012 Jun; 4(6):455-9. PubMed ID: 22511534
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport.
Guha N; Erotokritou-Mulligan I; Burford C; Strobridge G; Brigg J; Drake T; Bassett EE; Cowan D; Bartlett C; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2010 Jun; 95(6):2969-76. PubMed ID: 20410221
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
[TBL] [Abstract][Full Text] [Related]
6. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score.
Erotokritou-Mulligan I; Eryl Bassett E; Cowan DA; Bartlett C; Milward P; Sartorio A; Sönksen PH; Holt RI
Clin Endocrinol (Oxf); 2010 Apr; 72(4):520-6. PubMed ID: 19650783
[TBL] [Abstract][Full Text] [Related]
7. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
Kniess A; Ziegler E; Thieme D; Müller RK
J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
[TBL] [Abstract][Full Text] [Related]
8. Statistical methodology for age-adjustment of the GH-2000 score detecting growth hormone misuse.
Böhning D; Böhning W; Guha N; Cowan DA; Sönksen PH; Holt RI
BMC Med Res Methodol; 2016 Oct; 16(1):147. PubMed ID: 27793179
[TBL] [Abstract][Full Text] [Related]
9. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE
J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
[TBL] [Abstract][Full Text] [Related]
10. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
[TBL] [Abstract][Full Text] [Related]
11. Biomarker detection of rhGH doping: an excretion study.
Jing J; Zhou X; He C; Zhang L; Yang S; Xu Y; Xie M; Yan Y; Su H; Wu M
Drug Test Anal; 2012 Oct; 4(10):739-44. PubMed ID: 23074170
[TBL] [Abstract][Full Text] [Related]
12. Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting.
Healy ML; Dall R; Gibney J; Bassett E; Ehrnborg C; Pentecost C; Rosen T; Cittadini A; Baxter RC; Sönksen PH
J Clin Endocrinol Metab; 2005 Feb; 90(2):641-9. PubMed ID: 15546908
[TBL] [Abstract][Full Text] [Related]
13. Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes.
Di Luigi L; Rigamonti AE; Agosti F; Mencarelli M; Sgrò P; Marazzi N; Cella SG; Müller EE; Sartorio A
Eur J Endocrinol; 2009 May; 160(5):753-8. PubMed ID: 19258430
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport.
Abellan R; Ventura R; Pichini S; Pascual JA; Pacifici R; Di Carlo S; Bacosi A; Segura J; Zuccaro P
Clin Chem Lab Med; 2005; 43(1):75-85. PubMed ID: 15653447
[TBL] [Abstract][Full Text] [Related]
15. Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks' administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers.
Lehtihet M; Bhuiyan H; Dalby A; Ericsson M; Ekström L
Drug Test Anal; 2019 Mar; 11(3):411-421. PubMed ID: 30223291
[TBL] [Abstract][Full Text] [Related]
16. The effect of sports injury on insulin-like growth factor-I and type 3 procollagen: implications for detection of growth hormone abuse in athletes.
Erotokritou-Mulligan I; Bassett EE; Bartlett C; Cowan D; McHugh C; Seah R; Curtis B; Wells V; Harrison K; Sönksen PH; Holt RI;
J Clin Endocrinol Metab; 2008 Jul; 93(7):2760-3. PubMed ID: 18413420
[TBL] [Abstract][Full Text] [Related]
17. Moving one step closer to catching the GH cheats: The GH-2004 experience.
Holt RI; Bassett EE; Erotokritou-Mulligan I; McHugh C; Cowan D; Bartlett C; Sönksen PH;
Growth Horm IGF Res; 2009 Aug; 19(4):346-51. PubMed ID: 19467613
[TBL] [Abstract][Full Text] [Related]
18. Influence of ethnicity on IGF-I and procollagen III peptide (P-III-P) in elite athletes and its effect on the ability to detect GH abuse.
Erotokritou-Mulligan I; Bassett EE; Cowan DA; Bartlett C; McHugh C; Sönksen PH; Holt RI;
Clin Endocrinol (Oxf); 2009 Jan; 70(1):161-8. PubMed ID: 18616716
[TBL] [Abstract][Full Text] [Related]
19. Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration.
Cowan DA; Moncrieffe DA
Drug Test Anal; 2022 May; 14(5):808-819. PubMed ID: 34418311
[TBL] [Abstract][Full Text] [Related]
20. Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes.
Nelson AE; Howe CJ; Nguyen TV; Leung KC; Trout GJ; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
J Clin Endocrinol Metab; 2006 Nov; 91(11):4424-32. PubMed ID: 16912136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
